Founded in 2006, Anthem Biosciences Limited is a Contract Research, Development, and Manufacturing Organization (CRDMO) that provides comprehensive services throughout the drug development process—from discovery to manufacturing. The company specializes in producing fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, vitamin analogues, and biosimilars. It supports the full journey of commercial molecules, right from initial research to market launch. By September 30, 2024, Anthem had built a global presence, serving more than 425 clients in over 44 countries, including key markets like the U.S., Europe, and Japan. Its clientele ranges from small biotech startups to major pharmaceutical companies. Anthem is actively engaged in research and development, with 196 projects underway at different stages, including discovery, early and late development phases, and commercial production. The company also focuses on innovation, holding 8 granted patents (1 in India and 7 internationally), along with 24 pending patent applications worldwide. The company’s workforce, as of September 2024, consists of 600 professionals, including skilled chemists, biologists, and engineers with expertise across various scientific and technical fields.